Cixutumumab, ganitumab, robatumumab, and figitumumab, targeting the insulin-like growth factor-1 receptor (IGF1R), have been tested in advanced RMS, EWS, and osteosarcoma (28, 29). Here, IGF1R is linked to osteosarcoma.